| Keith G Holley, MD | |
|
4424 E Flamingo Ave, Suite 110, Nampa, ID 83687 | |
| (208) 288-4700 | |
| (208) 288-4720 |
| Full Name | Keith G Holley |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 30 Years |
| Location | 4424 E Flamingo Ave, Nampa, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386616183 | NPI | - | NPPES |
| 1386616183 | Medicaid | ID |
| Facility Name | Location | Facility Type |
|---|---|---|
| Treasure Valley Hospital | Boise, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allied Orthopaedics Llc | 8325351638 | 16 |
News Archive
Marijuana is the most commonly abused drug in the world, and the advent of synthetic cannabinoids creates additional challenges to the society because of their higher potency and ability to escape drug detection screenings.
National organizations will have a key role in building a healthier nation as part of the new U.S. Department of Health and Human Services (HHS) Communities Putting Prevention to Work initiative. HHS Secretary Kathleen Sebelius today announced a funding opportunity for national public or private non-profit organizations to apply for $10 million in cooperative agreements to help communities decrease smoking and obesity, increase physical activity and improve nutrition.
Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 8 days ago
| Entity Name | Allied Orthopaedics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750563540 PECOS PAC ID: 8325351638 Enrollment ID: O20150715002305 |
News Archive
Marijuana is the most commonly abused drug in the world, and the advent of synthetic cannabinoids creates additional challenges to the society because of their higher potency and ability to escape drug detection screenings.
National organizations will have a key role in building a healthier nation as part of the new U.S. Department of Health and Human Services (HHS) Communities Putting Prevention to Work initiative. HHS Secretary Kathleen Sebelius today announced a funding opportunity for national public or private non-profit organizations to apply for $10 million in cooperative agreements to help communities decrease smoking and obesity, increase physical activity and improve nutrition.
Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Keith G Holley, MD 3340 E Goldstone Way, Meridian, ID 83642-1026 Ph: (208) 367-5170 | Keith G Holley, MD 4424 E Flamingo Ave, Suite 110, Nampa, ID 83687 Ph: (208) 288-4700 |
News Archive
Marijuana is the most commonly abused drug in the world, and the advent of synthetic cannabinoids creates additional challenges to the society because of their higher potency and ability to escape drug detection screenings.
National organizations will have a key role in building a healthier nation as part of the new U.S. Department of Health and Human Services (HHS) Communities Putting Prevention to Work initiative. HHS Secretary Kathleen Sebelius today announced a funding opportunity for national public or private non-profit organizations to apply for $10 million in cooperative agreements to help communities decrease smoking and obesity, increase physical activity and improve nutrition.
Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 8 days ago
Charles Clark Iii, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9850 W St Lukes Dr, Nampa, ID 83687 Phone: 208-706-2663 Fax: 208-489-4300 | |
Dr. Jonathon Curtis Wolf, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9850 W St Lukes Dr Ste 215, Nampa, ID 83687 Phone: 208-706-2663 Fax: 208-489-4300 | |
Shane A Andrew, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4424 E Flamingo Ave, Suite 110, Nampa, ID 83687 Phone: 208-288-4700 Fax: 208-288-4720 | |
Tildon C Robinson Iv, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4424 E Flamingo Ave, Suite 110, Nampa, ID 83687 Phone: 208-288-4700 Fax: 208-288-4720 | |
Aaron Franklin Newton, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4400 E Flamingo Ave Ste 200, Nampa, ID 83687 Phone: 208-302-2700 Fax: 208-302-2725 | |
Jared T Armstrong, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9850 St Lukes Dr, Nampa, ID 83687 Phone: 208-706-2663 |